Screening stage | Treatment period (one day to three months after enrollment) | Evaluation period (once every three months for 24 months) | |
---|---|---|---|
Informed consent | X | ||
Demographic statistics | X | ||
History of present illness and treatment | X | ||
Symptoms and vital signs | X | X | X |
Inclusion/exclusion criteria | X | ||
Blood routine | X | X | X |
Blood biochemical test | X | X | X |
G test of peripheral blood | X | X | X |
GM test peripheral blood | X | X | X |
CD4/CD8 | X | X | X |
IgA, IgG, IgM | X | X | X |
HCG of peripheral blood or urine | X | ||
Noninvasive oxygen saturation | X | ||
Chest CT | X | X | X |
Electrocardiograph | X | X | X |
Fungal smear and culture | X | X | X |
Basic drugs and combined drugs | X | X | X |
Distribution of research drugs | X | ||
Recall of research drug | X | X | |
Evaluation of adverse events | X | X | X |
Schedule of next visit | X | X | |
Compliance evaluation | X | X | |
effectiveness evaluation | X | X | |
SGRQ score | X | X | X |
Evaluation of microbiological efficacy | X | X | |
Survival | X | X |